Pipeline
OKYO’s lead drug candidate, Urcosimod (0.05%), is a novel, non-opioid, preservative-free eye-drop therapy with dual pain-relieving and anti-inflammatory activity for neuropathic corneal pain (NCP)
Targeting High-Value, Underserved Rare Ocular Diseases
Pipeline Overview
Urcosimod
Indication
Preclinical
IND
Phase 1
Phase 2
Phase 3
Neuropathic Corneal Pain (NCP)
Phase 2/3 Topline Data Expected Q2 2027
Rare Corneal Disease
TBD
OK-201
Indication
Preclinical
IND
Phase 1
Phase 2
Phase 3
Discovery Program
Urcosimod Development Timeline
